Transrectal ultrasound biopsy of the prostate: Does it still have a role in prostate cancer diagnosis?

Andrew Moe, Dickon Hayne

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Transrectal ultrasound (TRUS) guided biopsy of the prostate has been a standard diagnostic approach for prostate cancer over the past thirty years. Today, the role of TRUS biopsy is being challenged by transperineal (TP) prostate biopsy due to concerns over the safety and diagnostic yield of TRUS biopsy. TRUS biopsy still offers a convenient, reliable and accessible tool for diagnosing prostate cancer in the majority of patients. It continues to play a role in prostate cancer diagnosis, especially where hospital resource allocation is limited, including the public sector. TRUS biopsy has low rates of severe complications, although there remains room for improvement in current practice to improve the tolerability and reduce the incidence of post-biopsy infection.

Original languageEnglish
Pages (from-to)3018-3024
Number of pages7
JournalTranslational Andrology and Urology
Volume9
Issue number6
DOIs
Publication statusPublished - Dec 2020

Fingerprint Dive into the research topics of 'Transrectal ultrasound biopsy of the prostate: Does it still have a role in prostate cancer diagnosis?'. Together they form a unique fingerprint.

Cite this